Market capitalization | $267.14m |
Enterprise Value | $83.61m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 1.66 |
EV/Sales (TTM) EV/Sales | 1.78 |
P/S ratio (TTM) P/S ratio | 5.70 |
P/B ratio (TTM) P/B ratio | 1.54 |
Revenue growth (TTM) Revenue growth | 4,516,931.76% |
Revenue (TTM) Revenue | $46.86m |
As a Free StocksGuide user, you can view scores for all 6,892 stocks worldwide.
3 Analysts have issued a AC Immune SA forecast:
3 Analysts have issued a AC Immune SA forecast:
Sep '24 |
+/-
%
|
||
Revenue | 47 47 |
-
|
|
Gross Profit | - - |
-
|
|
EBITDA | -40 -40 |
46%
46%
|
EBIT (Operating Income) EBIT | -42 -42 |
45%
45%
|
Net Profit | -45 -45 |
40%
40%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
AC Immune SA engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. It leverages proprietary technology platforms to discover, design, and develop novel, proprietary medicines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company was founded by Jean-Marie Lehn, Claude Nicolau, Roscoe Brady, Fred van Leuven, Ruth Greferath, Andrea Pfeifer, and Alexey V. Eleesiv on February 13, 2003 and is headquartered in Lausanne, Switzerland.
Head office | Switzerland |
CEO | Andrea Pfeifer |
Employees | 161 |
Founded | 2003 |
Website | www.acimmune.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.